Cibc World Market Inc. Has $26.92 Million Position in Bristol Myers Squibb Company $BMY

Cibc World Market Inc. lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 86.3% during the 4th quarter, HoldingsChannel reports. The firm owned 498,994 shares of the biopharmaceutical company’s stock after acquiring an additional 231,214 shares during the period. Cibc World Market Inc.’s holdings in Bristol Myers Squibb were worth $26,916,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Sivia Capital Partners LLC grew its holdings in shares of Bristol Myers Squibb by 464.6% during the fourth quarter. Sivia Capital Partners LLC now owns 47,322 shares of the biopharmaceutical company’s stock worth $2,553,000 after purchasing an additional 38,941 shares during the last quarter. Bowen Hanes & Co. Inc. bought a new position in Bristol Myers Squibb in the 4th quarter valued at approximately $542,000. Marietta Investment Partners LLC boosted its position in Bristol Myers Squibb by 50.8% during the 4th quarter. Marietta Investment Partners LLC now owns 54,562 shares of the biopharmaceutical company’s stock worth $2,943,000 after buying an additional 18,375 shares during the period. REAP Financial Group LLC grew its holdings in Bristol Myers Squibb by 26.1% during the 4th quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 182 shares during the last quarter. Finally, BlackDiamond Wealth Management LLC acquired a new position in Bristol Myers Squibb in the 4th quarter valued at approximately $203,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Trading Up 3.6%

BMY opened at $56.71 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a fifty day moving average of $58.13 and a 200-day moving average of $56.52. The stock has a market cap of $115.81 billion, a PE ratio of 15.93, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BMY shares. Guggenheim reiterated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.